Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances in studies of pressurized metered dose formulations containing hydrofluoroalkane propellants

( views:196, downloads:33 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 3

DOI:: 10.3321/j.issn:0513-4870.2006.03.002

Key Word:: 定量吸入气雾剂;氟里昂;氢氟烷

Abstract： @@ 1前言肺部药物传递系统(pulmonary drug delivery system,PDDS)可应用于局部或全身输送药物,达到预防、诊断或治疗的目的.1955年由RikerLaboratories(现为3M公司)发明的以氟利昂(CFC)为抛射剂的定量吸入气雾剂(pressurized metered dose inhaler,MDI)一直为肺部吸入剂型的首选.但由于国际社会应环境保护的要求而逐步禁用CFC,人们不得不寻找不含CFC的新型PDDS.有关研究在过去的十多年里取得了两方面重要进展:一方面,以干粉吸入剂(DPI)替代MDI,因为DPI无需使用抛射剂;另一方面,开发新的环保型抛射剂,如氢氟烷(HFA)替代传统CFC.

Reference

[1]J G, Hardy,T S, Chadwick.Sustained release drug delivery to the lungs: an option for the future.[J].2000,39.
[2]Masahiro Sakagami,Kiyoyuki Sakon,Wataru Kinoshita,etc.Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres[J].2001,77(1-2).
[3]Bowman PA,Greenleaf D.Non-CFC metered dose inhalers: the patent landscape.[J].1999,186(1).
[4]D A, Edwards,J, Hanes,G, Caponetti,etc.Large porous particles for pulmonary drug delivery.[J].1997,276.
[5]Kellaway IW,Dickinson PA,Gumbleton M,etc.Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383.[J].2002,54(8).
[6]Palakodaty S,York P.Phase behavioral effects on particle formation processes using supercritical fluids.[J].1999,16(7).
[7]N Butz,C Porté,H Courrier,etc.Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants[J].2002,238(1-2).
[8]Steckel H,Wehle S.A novel formulation technique for metered dose inhaler (MDI) suspensions.[J].2004,284(1).
[9]Liao YH,Brown MB,Nazir T,etc.Effects of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme.[J].2002,19(12).
[10]Weers JG,Adractas A,Costello ML,etc.Hollow porous particles in metered dose inhalers.[J].2000,17(2).
[11]Abhishek, Gupta,Stephen W, Stein,Paul B, Myrdal.Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers.[J].2003,16(2).
[12]Williams, R. O.,Barron, M. K.,Jose Alonso, M.,etc.Investigation of a pMDI system containing chitosan microspheres and P134a[J].1998,174(1).
[13]Hirst PH,Clark AR,Pitcairn GR,etc.In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler.[J].2002,19(3).
[14]R O, Williams,J, Brown,J, Liu.Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation.[J].1999,4.
[15]Maa YF,Nguyen PA,Sweeney T,etc.Protein inhalation powders: spray drying vs spray freeze drying.[J].1999,16(2).
[16]Xian Ming Zeng,Gary Peter Martin,Christopher Marriott.The controlled delivery of drugs to the lung[J].1995,124(2).
[17]Myrdal PB,Haynes A,Stein SW,etc.Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers.[J].2004,93(4).
[18]Anthony J. Hickey,Richard N. Dalby,Peter R. Byron.Effects of surfactants on aerosol powders in suspension. Implications for airborne particle size[J].1988,42(1-3).
[19]Daniel Mufson,Alejandro Zaffaroni,Ron Hale,etc.Fast Onset Medications through Thermally Generated Aerosols[J].2004,309(2).
[20]Lengsfeld C,Ruth JA,Claffey DJ,etc.Hydrophobic ion pairing of isoniazid using a prodrug approach.[J].2002,91(6).
[21]Labiris NR,Dolovich MB.Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.[J].2003,56(6).
[22]Price R,Kaerger JS.Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique.[J].2004,21(2).
[23]Gupta A,Myrdal PB.Novel method for the determination of solubility in aerosol propellants.[J].2004,93(10).
[24]Phillips, E. M.,Byron, P. R..Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane[J].1994,110(1).
[25]Mishra V,Vyas SP,Jain S,etc.Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.[J].2004,269(1).
[26]P A, Dickinson,P C, Seville,H, McHale,etc.An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.[J].2000,13(3).
[27]Vidgren, M.,Waldrep, J. C.,Arppe, J.,etc.A study of ^9^9^mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers[J].1995,115(2).
[28]Hartman MS,Weers JG,Tarara TE,etc.Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.[J].2004,21(9).
[29]Muller BW,Rasenack N,Steckel H.Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process.[J].2003,92(1).
[30]Stein SW,Myrdal PB.A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions.[J].2004,93(8).
[31]Hanes J,Fiegel J,Fu J,etc.New polymeric carriers for controlled drug delivery following inhalation or injection.[J].2002,23(22).
[32]Quinn EA,Williams AC,Oliver MJ,etc.Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy.[J].1999,186(1).
[33]R O, Williams,M A, Repka,M K, Barron.Application of co-grinding to formulate a model pMDI suspension.[J].1999,48(2).